Evaluate Manufacturing Control
Assess whether production, packaging, laboratory and release activities are performed consistently under controlled and documented conditions.
Independent, risk-based GMP audits for pharmaceutical, biotechnology, manufacturing, laboratory, packaging and supply-chain organizations seeking stronger product quality, reliable operations, effective quality systems and inspection-ready facilities.
GMP audits assess whether facilities, systems, documentation and operational controls consistently support product quality, process reliability and compliance with applicable manufacturing expectations.
Assess whether production, packaging, laboratory and release activities are performed consistently under controlled and documented conditions.
Review deviations, CAPA, change control, complaints, training, management review and quality oversight for evidence of sustainable control.
Evaluate suppliers, contract manufacturers, laboratories and other critical service providers supporting GMP-regulated activities.
GMP weaknesses often emerge where documentation, process execution, investigation quality, supplier oversight and management visibility do not operate as one controlled system.
Investigations do not identify systemic root causes, actions do not address recurrence and effectiveness checks provide limited evidence of risk reduction.
Batch records, laboratory records, corrections, audit trails or electronic data do not provide complete and reliable evidence of manufacturing activities.
Qualification, quality agreements, change notification, performance monitoring and escalation are not consistently managed.
Equipment, cleaning, environmental, contamination or maintenance controls do not consistently support reliable production.
Audit scope can focus on a facility, system, process, supplier, contract manufacturer or critical compliance concern.
Independent assessment of manufacturing operations, facility control, equipment, personnel practices and quality oversight.
Evaluation of laboratory governance, methods, data integrity, equipment, investigations and release-support activities.
Qualification and oversight audits for contract manufacturing and development organizations supporting regulated products.
Independent qualification and oversight of material, component, packaging and critical service suppliers.
Focused assessment of the systems used to govern compliance, investigate problems, manage change and sustain control.
Focused independent review where recurring failures, serious deviations, data integrity concerns or potential product-quality risk require urgent assessment.
The final scope is adapted to the product, facility, manufacturing stage, supply-chain model, known risks and intended business outcome.
The process is designed to provide objective findings, clear risk classification and practical recommendations for QA, operations and leadership.
Understand the product, facility, process, supplier relationship, previous findings and business purpose of the audit.
Define audit criteria, documentation needs, sampling strategy, interviewees and high-risk systems requiring deeper assessment.
Review SOPs, quality records, batch documentation, validation files, site information and available performance data.
Conduct interviews, facility walkthroughs, process observation, document review, record sampling and system demonstrations.
Assess significance, recurrence, systemic impact and potential effect on product quality, patient safety and regulatory compliance.
Deliver risk-ranked findings, recommendations and optional CAPA review or effectiveness verification support.
Deliverables can be adapted to supplier qualification, inspection readiness, routine oversight, transaction due diligence or for-cause review.
GMP audits can support qualification, routine oversight, inspection preparation, due diligence or urgent independent review.
A critical supplier, CMO or laboratory must be assessed before use or contract renewal.
The organization requires independent assurance over facility, documentation and quality-system readiness.
Repeat failures indicate possible systemic weaknesses in investigation, CAPA or operational control.
Laboratory, manufacturing or electronic records require focused independent review.
New processes, products or manufacturing responsibilities require assurance over readiness and control.
Responsibilities between sponsor, manufacturer, laboratory or supplier require clarification and stronger governance.
A facility, manufacturing platform or acquisition target requires compliance and quality-risk assessment.
Serious product, process or compliance concerns require confidential independent assurance.
Independent GMP audits help organizations identify weaknesses earlier, strengthen manufacturing governance and improve confidence in product, supplier and quality-system control.
Identify weaknesses in production, laboratory, documentation and release controls before they create product or patient risk.
Improve qualification, quality agreement governance, performance monitoring and escalation across the supply chain.
Strengthen evidence, process ownership and quality-system visibility before regulatory or client scrutiny.
Common questions from pharmaceutical, biotechnology, manufacturing and supply-chain organizations considering independent GMP audit support.
Yes. Depending on the scope, documentation, systems and facility access, selected quality-system, supplier, laboratory and document audits can be delivered remotely or through a hybrid model.
Yes. Qualification, requalification and oversight audits can be performed for CMOs, CDMOs, contract laboratories and critical service providers.
Yes. The scope can focus on deviations, CAPA, change control, data integrity, complaints, supplier oversight, laboratory systems or another defined GMP process.
Yes. Support can include root cause review, CAPA adequacy assessment, remediation planning and follow-up effectiveness verification.
Yes. For-cause audits can be conducted confidentially when serious product, process, supplier or data-integrity concerns require independent review.
Yes. GMP audit engagements are handled confidentially, and NDA-based collaboration can be used where required.